RBM15 and ZMYND8 shape acute myeloid leukemia response to BCL2 inhibitors

Key Points

• The aim is to understand how RBM15 and ZMYND8 affect the response of acute myeloid leukemia to BCL2 inhibitors.
• Analyzed RBM15 and ZMYND8 expression levels
• Evaluated cellular response to BCL2 inhibitors
• Used molecular pathway assessments
• Altered RBM15 and ZMYND8 levels changed leukemia cell sensitivity to BCL2 inhibitors
• Significant impacts on treatment outcomes observed
• Identified potential molecular targets for enhancing BCL2 inhibitor efficacy